• XAV-939 in Osteogenic Differentiation: Beyond Wnt Pathway In

  2026-05-28

  Explore how XAV-939, a potent tankyrase inhibitor, uniquely advances osteogenic differentiation and bone formation research. This article offers new insights into assay design by connecting XAV-939’s mechanisms with the latest findings on Wnt signaling and metabolic regulation.

• FITC-Concanavalin A (ConA) Conjugate: Protocols and QC Guide

  2026-05-27

  FITC-Concanavalin A (ConA) Conjugate enables direct, fluorescence-based detection of α-D-glucose and α-D-mannose residues on cell surfaces, supporting immunofluorescence and flow cytometry workflows in glycobiology research. It should not be used for non-carbohydrate-binding assays or outside its defined storage and stability parameters. Proper handling ensures specific and reliable cell surface carbohydrate detection.

• Tacrine Hydrochloride Hydrate: Protocols for Alzheimer's Res

  2026-05-27

  Tacrine hydrochloride hydrate stands out as a gold-standard tool for robust cholinesterase inhibition, neuroprotection, and benchmarking in Alzheimer's disease research. This article unpacks practical workflows, troubleshooting strategies, and the latest cross-enzyme metabolism insights to empower reproducible results in neurodegenerative disease models.

• Bufuralol Hydrochloride: Advancing β-Adrenergic Research Pre

  2026-05-26

  Discover how Bufuralol hydrochloride, a non-selective β-adrenergic receptor antagonist, is transforming cardiovascular pharmacology research with nuanced partial agonism and innovative in vitro assay strategies. This article offers new insight into protocol optimization and the impact of hiPSC-derived intestinal organoid models.

• (R,S)-Anatabine for Precision Soluble Aβ Reduction in AD Mod

  2026-05-26

  (R,S)-Anatabine offers Alzheimer’s researchers an evidence-backed, dual-mechanism approach to soluble Aβ peptide reduction—targeting both amyloidogenic processing and neuroinflammation. This guide details protocol specifics, advanced troubleshooting, and actionable insights for maximizing translational value in both in vitro and in vivo Alzheimer’s disease models.

• Syringin Natural Product: Applied Workflows in RCC Research

  2026-05-25

  Syringin, a high-purity natural product from APExBIO, is redefining renal cell carcinoma (RCC) research by targeting the EGFR/PI3K/Akt pathway and boosting sunitinib efficacy. This guide delivers hands-on workflow enhancements, troubleshooting strategies, and actionable assay design informed by the latest peer-reviewed evidence.

• RNASEH1-AS1: Prognostic lncRNA and Oncogenic Target in HCC

  2026-05-25

  This study comprehensively characterizes the long non-coding RNA RNASEH1-AS1 as a novel biomarker and potential therapeutic target in hepatocellular carcinoma (HCC). Through integrative data analysis and experimental validation, RNASEH1-AS1 is shown to drive tumor progression and correlate with poor prognosis, providing new insight into lncRNA-mediated oncogenesis.

• Supercritical Angle Spectroscopy Reveals Calcium’s Role in A

  2026-05-24

  This study employs supercritical angle Raman and fluorescence spectroscopy to elucidate how calcium ions modulate amyloid beta aggregation at membrane interfaces, a key process in Alzheimer’s disease pathology. The findings clarify the nuanced influence of Ca2+ on peptide-membrane interactions, offering mechanistic insight and advancing analytical approaches for aggregation research.

• MLKL Polymerization Drives Lysosomal Permeabilization in Nec

  2026-05-23

  The referenced study unveils a mechanistic link between MLKL polymerization and lysosomal membrane permeabilization (LMP) during necroptosis. By demonstrating that MLKL-induced LMP precedes plasma membrane rupture and facilitates cathepsin-mediated cell death, this work advances our molecular understanding of regulated necrosis and highlights novel intervention points for cell death modulation.

• Technical Guidance for Triamcinolone in Glucocorticoid Resea

  2026-05-22

  Triamcinolone is a synthetic glucocorticoid agonist designed for controlled studies of glucocorticoid signaling, anti-inflammatory mechanisms, and immunosuppression in vitro. This product is not intended for diagnostic or clinical use, and precise handling is essential to maintain stability and data integrity.

• Patient-Derived Gastric Cancer Assembloids: Modeling Tumor–S

  2026-05-22

  This study introduces a patient-derived gastric cancer assembloid model that integrates matched tumor organoids with stromal cell subpopulations, achieving greater physiological relevance than conventional organoid systems. These assembloids reveal new insights into tumor–stroma interactions and drug resistance, paving the way for improved preclinical drug testing and personalized therapy strategies.

• Novel Triazole ALDH2 Activators Mitigate Myocardial Ischemia

  2026-05-21

  This study introduces a new class of triazole-based aldehyde dehydrogenase 2 (ALDH2) activators, optimized for solubility and bioactivity, that significantly protect cardiac tissue in mouse models of myocardial ischemia-reperfusion. The lead compound, Z17, outperformed existing activators, offering a promising avenue for targeted MI therapeutics and highlighting a methodology for rational drug design in enzyme modulation.

• Taltirelin Acetate: Mechanisms and Applications in Neuroprot

  2026-05-21

  Taltirelin acetate, a long-acting TRH analog, selectively activates TRH receptor 1 and modulates neuroendocrine function. It shows sustained efficacy in preclinical OSA models and is validated in neurodegeneration and bioequivalence research. This article summarizes key benchmarks, protocols, and practical boundaries for Taltirelin use.

• Novobiocin: Mechanistic Depth and Translational Leverage

  2026-05-20

  This thought-leadership article synthesizes the dual mechanistic actions of Novobiocin—an aminocoumarin antibiotic and Hsp90 inhibitor—with strategic, evidence-based guidance for translational researchers. By integrating mechanistic insight, protocol optimization, and emerging combination data, we explore Novobiocin’s unique translational value in antibacterial resistance, antiparasitic, and antiviral studies. Drawing on recent peer-reviewed data and scenario-driven workflow advances, this piece offers actionable strategies for maximizing discovery impact and bridging the gap from bench to bedside.

• (R,S)-Anatabine in Alzheimer's Disease Models: Applied Use-C

  2026-05-20

  (R,S)-Anatabine enables targeted, reproducible amyloid-beta reduction in both in vitro and in vivo Alzheimer’s disease workflows, distinguishing itself through a dual action on amyloidogenic processing and neuroinflammation. This article details practical integration strategies, protocol parameters, and troubleshooting approaches for maximizing performance in neurodegeneration research.

405 records 7/27 page Previous Next First page 上5页 678910 下5页 Last page